Human PAI-1 Platinum ELISA

Description: The human PAI-1 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human PAI-1. The human PAI-1 ELISA is for research use only. Not for diagnostic or therapeutic procedures.

Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of plasminogen activators in plasma, rapidly inactivating both tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). PAI-1 is a single-chain glycoprotein with a molecular weight of 47 kilodaltons. During fibrinolysis, tissue plasminogen activator (tPA) converts the inactive protein plasminogen into plasmin which plays a critical role in fibrinolysis by degrading fibrin and providing localized protease activity in a number of physiological functions. PAI-1 is synthesized in the liver and by endothelial cells, and its synthesis is regulated by several physiologic mediators, including endotoxin, interleukin-1, fibroblast growth factor-2, and lipids.

Plasminogen activator inhibitor-1 is an important inhibitor of the fibrinolytic system, so elevated levels could suppress fibrinolysis and result in an increased risk of thrombosis. Increased PAI-1 levels have been shown to be associated with a number of atherosclerotic risk factors, PAI-1 has been shown to act as a prothrombic factor in both arterial and venous thromboembolic disorders. Increased levels of PAI-1 are associated with an increased incidence of acute coronary syndrome.
PAI-1 levels are also increased in patients with chronic and acute coronary artery disease (CAD) and in patients who suffer restenosis after coronary angioplasty.

References: Huber,K.. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J.Thromb.Thrombolysis. 2001;11:183-193. (Link)

Huber,K.; Christ,G.; Wojta,J.; Gulba,D.. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb.Res. 2001;103 Suppl :S7-19. (Link)

Huber,K.. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. J.Thromb.Thrombolysis. 2001;11:195-202. (Link)

Adcock,D.M.; Kressin,D.C.; Marlar,R.A.. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am.J.Clin.Pathol. 1997;107:105-110. (Link)